Publications by authors named "Pamela Sawatzky"
Article Synopsis
- Gonorrhea is a major public health issue in Canada, being the second most common bacterial STI, and the Gonococcal Antimicrobial Surveillance Programme has been tracking its antimicrobial resistance since 1985.
- In 2021, Canada saw a 9.9% increase in gonococcal cultures submitted, revealing growing resistance to cefixime and identifying one ceftriaxone-resistant isolate, despite no significant changes in ceftriaxone resistance overall.
- The monitoring highlights a significant public health threat due to rising antimicrobial resistance, underscoring the necessity for ongoing surveillance to inform effective treatment options.*
Background: The Gonococcal Antimicrobial Surveillance Programme is a passive surveillance system that has monitored antimicrobial resistance in in Canada since the 1980s. This article summarizes the demographics, antimicrobial resistances and NG-MAST ( multiantigen sequence typing) for cultures collected in 2020.
Methods: The National Microbiology Laboratory (NML) in Winnipeg received resistant cultures from provincial and territorial public health laboratories.
Background: Ciprofloxacin (500 mg orally, single dose) is one of the recommended therapies for gonorrhea in Canada. In Canada, the first ciprofloxacin-resistant (CipR) Neisseria gonorrhoeae strain was isolated in 1993. Antimicrobial susceptibilities of N gonorrhoeae isolates were monitored as part of a national surveillance program to ensure efficacy of antimicrobial therapies.
View Article and Find Full Text PDF